Verastem: Novel Drugs Targeting the Tumor Microenvironment

Verastem Inc. (NASDAQ: VSTM) is a clinical stage biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem's product candidates seek to treat cancer by targeting malignant cells both directly and through modulation of the tumor microenvironment. Our most advanced programs target the phosphoinositide-3-kinase (PI3K) and Focal Adhesion Kinase (FAK) pathways.

 

 

ANNOUNCEMENTS

December 11, 2017
Verastem Announces the Presentation of Phase 1 Duvelisib Combination Data in T-Cell Lymphomas at the ASH 2017 Annual Meeting

December 10, 2017
Verastem Announces Clinical Data from the Pivotal Phase 3 DUO™ Study: Duvelisib Significantly Improves Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

December 5, 2017
Verastem to Present Results from Pivotal Phase 3 DUO Study in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at a Research and Development Event at ASH 2017

 

CHALLENGES IN TREATING CANCER:

Major advances in cancer treatment have led to significant improvements in efficacy. However, this benefit does not extend to all patients. Challenges in the tumor microenvironment may both support tumor survival, and inhibit anti-tumor activity of cancer therapies and adaptive immune response.

Learn More »